This analysis correlated with the increased expression of HNRNPM with poorer disease-free survival over time, while this was not the case for HNRNPF (Figure 1—figure supplement 1B). Analysis of HNRNPM mRNA expression in normal and tumor prostate adenocarcinoma (PRAD) patient samples in the same datasets suggested that HNRNPM mRNA expression levels were significantly higher in tumor samples when compared with normal controls (Figure 1—figure supplement 1C). This evidence concerns the gene HNRNPF and neoplasm.